Get started

Financials · INBS

Intelligent Bio Solutions Inc. (INBS) financials

For fiscal 2026 (ended Jun 30, 2026), Intelligent Bio Solutions Inc. reported $4.22M of revenue and -$12.43M of net income.

Revenue, FY2026
$4.22M
Revenue growth, YoY
+38.1%
Net income, FY2026
-$12.43M
Net margin
-294.9%
Free cash flow, FY2026
-$12.05M
EPS, diluted, FY2026
-$8.44
Cash
$3.99M
Total debt
$0
P/S
1.80
Market cap
$7.6M
Annual revenue$4.22M
FY2020FY2026
Annual net income-$12.43M
FY2020FY2026
Annual free cash flow-$12.05M
FY2024FY2026

INBS revenue and earnings growth

INBS revenueQ4 2026$1.15M

Quarter YoY
+35.8%
QoQ
+8.0%
FY YoY
+38.1%
5Y CAGR
+16.3%

INBS revenue was $1.15M in fiscal Q4 2026 (ended Jun 30, 2026), up 35.8% from a year earlier and up 8.0% from the prior quarter. For the full fiscal 2026 it was $4.22M, up 38.1% from fiscal 2025. Compound annual growth was +16.3% over 5 years. It rose in 4 of the last 6 fiscal years. Fiscal 2026 is the highest of the 7 fiscal years on file.

INBS net incomeQ4 2026-$3.91M

INBS net income was -$3.91M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$3.09M a year earlier. For the full fiscal 2026 it was -$12.43M, compared with -$10.57M in fiscal 2025.

INBS EPSFY2026-$8.44

INBS diluted EPS was -$8.44 for fiscal 2026 (ended Jun 30, 2026).

INBS free cash flowQ4 2026-$3.18M

INBS free cash flow was -$3.18M in fiscal Q4 2026 (ended Jun 30, 2026). For the full fiscal 2026 it was -$12.05M, compared with -$9.91M in fiscal 2025.

Export CSV

Income statement

Income statement
Line item
FY2026
Jun 30, 2026
FY2025
Jun 30, 2025
FY2024
Jun 30, 2024
FY2023
Jun 30, 2023
FY2022
Jun 30, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
Revenue$4.22M$3.05M$3.11M$1.26M$437.1K$1.98M$188.7K
Cost of revenue$2.17M$1.81M$1.69M$930.2K---
Gross profit$2.05M$1.25M$1.43M$326.7K---
Selling, general and admin$10.50M$8.92M$9.26M$8.03M$4.92M$3.36M$2.20M
Operating income-$12.61M-$10.68M-$10.28M-$12.60M-$8.34M-$5.57M-$2.86M
Interest expense$10.7K$26.3K$167.1K----
Pre-tax income------$7.06M-$3.19M
Net income-$12.43M-$10.57M-$10.16M-$10.63M-$8.31M-$7.04M-$3.16M
EPS, basic-$8.44-$20.04-$63.80-$1270.00-$113.30-$6.80-$3.70
EPS, diluted-$8.44-$20.04-$63.80-$1270.00-$113.30-$6.80-$3.70
Diluted shares1.5M527,364159,274.68,371.773,326.31.0M851,032.9

Balance sheet

Balance sheet
Line item
FY2026
Jun 30, 2026
FY2025
Jun 30, 2025
FY2024
Jun 30, 2024
FY2023
Jun 30, 2023
FY2022
Jun 30, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
Cash and equivalents$3.99M$1.02M$6.30M$1.54M$8.24M$12.57M$427.3K
Receivables$848.5K$594.6K$429.7K$293.9K---
Inventory$418.6K$635.2K$777.5K$979.9K---
Current assets$7.10M$4.14M$8.53M$3.86M$10.87M$18.21M$2.34M
Total assets$11.94M$8.25M$13.78M$10.35M$12.35M$21.86M$2.48M
Current liabilities$4.93M$5.35M$5.45M$5.88M$4.66M$3.68M$7.69M
Total debt$0------
Total liabilities$6.65M$5.44M$5.60M$6.67M$5.81M$6.85M$7.69M
Shareholders' equity$5.51M$3.00M$8.18M$3.69M$6.55M$15.01M-$5.21M

Cash flow

Cash flow
Line item
FY2026
Jun 30, 2026
FY2025
Jun 30, 2025
FY2024
Jun 30, 2024
FY2023
Jun 30, 2023
FY2022
Jun 30, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
Operating cash flow-$11.93M-$9.68M-$9.57M-$7.38M-$3.36M-$11.30M-$498.6K
Capital expenditures$125.7K$231.8K$221.4K----
Free cash flow-$12.05M-$9.91M-$9.79M----
Investing cash flow-$85.6K-$231.8K-$221.4K-$694.1K-$880.2K--$14.0K
Financing cash flow$14.98M$4.60M$14.56M$1.44M-$23.40M$733.9K
Stock-based compensation$195.2K$238.0K$230.5K$260.0K---
Depreciation and amortization$1.16M$1.21M$974.4K$814.5K---

Key ratios

Key ratios
Line item
FY2026
Jun 30, 2026
FY2025
Jun 30, 2025
FY2024
Jun 30, 2024
FY2023
Jun 30, 2023
FY2022
Jun 30, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
Revenue growth, YoY38.1%-1.9%147.6%187.5%-77.9%949.3%-
Gross margin48.6%40.8%45.8%26.0%---
Operating margin-299.1%-349.8%-330.5%-1002.1%-1907.1%-281.4%-1513.7%
Net margin-294.9%-346.2%-326.4%-845.9%-1900.1%-355.3%-1676.2%
Free cash flow margin-285.9%-324.6%-314.7%----
Return on equity-225.6%-352.7%-124.1%-288.4%-126.9%-46.9%-
Return on assets-104.1%-128.1%-73.7%-102.7%-67.2%-32.2%-127.8%
Current ratio1.440.771.570.662.334.940.30
Debt to equity0.00------

Source: XBRL data Intelligent Bio Solutions Inc. files with the SEC, latest filing dated Aug 19, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Feb 12, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

INBS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
INBS$4.22M+38.1%-$12.43M-294.9%$7.6M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

INBS FAQ

9 questions
  • What is INBS revenue?
    Intelligent Bio Solutions Inc. (INBS) reported $4.22M of revenue for fiscal 2026 (ended Jun 30, 2026). That is up 38.1% from the year before.
  • Is INBS profitable?
    No. Intelligent Bio Solutions Inc. reported a net loss of $12.43M for fiscal 2026 (ended Jun 30, 2026).
  • How much cash and debt does INBS have?
    Intelligent Bio Solutions Inc. reported $3.99M in cash and cash equivalents and $0 of debt on its most recent balance sheet in SEC filings.
  • How fast is INBS revenue growing?
    Intelligent Bio Solutions Inc.'s revenue changed +38.1% in fiscal 2026, to $4.22M. Its compound annual growth rate was +16.3% over 5 years.
  • What is INBS gross margin?
    Intelligent Bio Solutions Inc.'s gross profit was $2.05M on $4.22M of revenue for fiscal 2026 (ended Jun 30, 2026), a gross margin of 48.6%.
  • What is INBS free cash flow?
    Intelligent Bio Solutions Inc. generated -$12.05M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -$11.93M less capital expenditures.
  • What is INBS earnings per share?
    Diluted earnings per share were -$8.44 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.
  • When did INBS last report financial results?
    The latest statements here come from Intelligent Bio Solutions Inc.'s 10-K filed on Aug 19, 2026, covering the period ended Jun 30, 2026.
  • Where does this INBS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Intelligent Bio Solutions Inc. files with the SEC. It is provided for information only and is not investment advice.